258 results
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
19 Aug 13
Other Events
12:00am
participated in the POWER1 and POWER2 clinical trials in order to make it possible for future patients to potentially have access to important therapies … (866) 700-5192 (domestic) or (617) 213-8833 (international). The access code is 35408233. A replay of the discussion will be available beginning
DEFA14A
ONCT
Oncternal Therapeutics Inc
26 Apr 24
Additional proxy soliciting materials
4:15pm
. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy … -mail requesting material. Have the 12 digit control number located in the box above available when you access the website and follow the instructions
DEFA14A
ONCT
Oncternal Therapeutics Inc
16 May 23
Additional proxy soliciting materials
4:12pm
For Stockholders of record as of May 09, 2023 Have the 12 digit control number located in the shaded box above available when you access the website and follow … to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all
DEFA14A
ONCT
Oncternal Therapeutics Inc
13 Apr 21
Additional proxy soliciting materials
4:16pm
that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all … located in the shaded box above available when you access the website and follow the instructions. If you want to receive a paper or e-mail copy
8-K
EX-99.1
9r7wdfy7dgzlo e7feg
7 Sep 06
Regulation FD Disclosure
12:00am
8-K
EX-99.1
6uyq3s vgbu71o
8 May 12
GTx PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS
12:00am
DEFA14A
f6cvg42
29 Apr 22
Additional proxy soliciting materials
10:10am
8-K
EX-99.1
etx3cy5b91msn
8 May 12
Other Events
12:00am
8-K
EX-99.1
8arekt
2 Nov 09
GTx Receives Complete Response Letter from FDA for Toremifene 80 mg New Drug Application
12:00am
8-K
EX-99.1
8552 vtt1hj
21 Feb 12
GTx Announces Clinical Hold on Clinical Trials Evaluating Capesaris® for First and Second Line Treatments of Advanced Prostate Cancer
12:00am
8-K
EX-99.1
sjd85zay
6 Nov 08
GTX, Inc. Reports Third Quarter 2008 Financial Results
12:00am
8-K
EX-99.1
rjefi so2
27 Apr 06
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
3d76i3j3 3l0ba88
21 Feb 13
GTx PROVIDES CORPORATE UPDATE AND REPORTS 2012 FINANCIAL RESULTS
12:00am
8-K
EX-99.1
qt2iy 7z5na18
15 Mar 10
GTx PROVIDES CORPORATE UPDATE AND REPORTS 2009 FINANCIAL RESULTS
12:00am
8-K
EX-99.1
ufcfbvbbl6djs7
15 Dec 05
Other Events
12:00am
8-K
EX-99.1
8kmq4p
3 Mar 08
Other Events
12:00am
S-4
EX-10.55
fb3gj 6vdyq
5 Apr 19
Registration of securities issued in business combination transactions
9:02pm
8-K
EX-99.1
kqj2a k792fgf5u
10 Aug 09
GTX, Inc. Reports Second Quarter 2009 Corporate Results
12:00am